Citations

Clear

27 citation(s) found for "Shaaban, M".

Repeat Single-Session Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations: A Systematic Review, Meta-Analysis, and International Stereotactic Radiosurgery Society Practice Guidelines
Shaaban, Ahmed , Tos, Salem M , Mantziaris, Georgios , Kotecha, Rupesh , Gorgulho, Alessandra, Ma, Lijun , Pollock, Bruce E. , Régis, Jean , Yomo, Shoji , Sahgal, Arjun , Sheehan, Jason P. , Sheehan, Jason , Mantziaris, Georgios , Fariselli, Laura , Levivier, Marc , Paddick, Ian , Suh, John H.

Mayo Clinic

Neurosurgery | June 24, 2024 | Volume: 96 | Issue: 1 | Pages: 29-40

10.1227/neu.0000000000003049 | PMID 38912814 Get It

BACKGROUND AND OBJECTIVES: Repeat stereotactic radiosurgery (SRS) for residual arteriovenous malformations (AVMs) can be considered as a salvage approach after failure of initial SRS. There are no published guidelines regarding patient selection, timing, or SRS parameters to guide clinical practice. This systematic review aimed to review outcomes and complications from the published literature to inform practice recommendations provided on behalf of the International Stereotactic Radiosurgery Society. METHODS: We performed a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search of MEDLINE, Scopus, Web of Science, and Embase was conducted. Fourteen studies with 925 patients met the inclusion criteria. Patients were treated between 1985 and 2022. All studies were retrospective, except for one prospective cohort. RESULTS: The median patient age at repeat SRS ranged from 32 to 60 years. Four studies (630 patients) reported detailed information on Spetzler–Martin grade at the time of repeat SRS; 12.54% of patients had Spetzler–Martin grade I AVMs (79/630 patients), 46.51% had grade II (293/630), 34.92% had grade III (220/630), 5.08% had grade IV (32/630), and 0.95% had grade V (6/630). The median prescription doses varied between 15 and 25 Gy (mean, 13.06-22.8 Gy). The pooled overall obliteration rate at the last follow-up after repeat SRS was 59% (95% CI 51%-67%) with a median follow-up between 21 and 50 months. The pooled hemorrhage incidence at the last follow-up was 5% (95% CI 4%-7%), and the pooled overall radiation-induced change incidence was 12% (95% CI 7%-20%). CONCLUSION: For an incompletely obliterated AVM, repeat radiosurgery after 3 to 5 years of follow-up from the first SRS provides a reasonable benefit to the risk profile. After repeat SRS, obliteration is achieved in the majority of patients. The risk of hemorrhage or radiation-induced change appears low, and International Stereotactic Radiosurgery Society recommendations are presented.
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective
Aggarwal, Neelum T. , Vila‐Castelar, Clara , Brugulat‐Serrat, Anna , Foldi, Nancy S. , Gilsanz, Paola , Li, Wei , McManus, Alison J. , Lent, Debora Melo van , Milani, Sadaf Arefi , Shaaban, C. Elizabeth , Stites, Shana D. , Trani, Jean‐Francoise, Turner, Arlener D. , Vonk, Jet M. J. , Quiroz, Yakeel T. , Group, for the Diversity and Disparity Professional Interest Area Sex and Gender Special Interest, Mielke, Michelle M. , Agarwal, Puja , Arenaza‐Urquijo, Eider M. , Brett, Benjamin L. , DuBose, Lyndsey Elisabeth , Eikelboom, Willem S. , Flatt, Jason D. , Franzen, Sanne , Sundermann, Erin E. , Suryadevara, Vidyani , Babulal, Ganesh M. , Group, for the Diversity and Disparity Professional Interest Area Sex and Gender Special Interest

Mayo Clinic

Alzheimer's & Dementia | April 8, 2022 | Volume: 18 | Issue: 12 | Pages: 2707-2724

10.1002/alz.12662 | PMID 35394117 Get It

Abstract Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention. However, few epidemiological or clinical ADRD studies examine sex differences; even fewer evaluate gender in the context of ADRD risk. The goals of this perspective are to: (1) provide definitions of gender, biologic sex, and sexual orientation. and the limitations of examining these as binary variables; (2) provide an overview of what is known with regard to sex and gender differences in the risk, prevention, and diagnosis of ADRD; and (3) discuss these sex and gender differences from a global, worldwide perspective. Identifying drivers of sex and gender differences in ADRD throughout the world is a first step in developing interventions unique to each geographical and sociocultural area to reduce these inequities and to ultimately reduce global ADRD risk. Highlights The burden of dementia is unevenly distributed geographically and by sex and gender. Scientific advances in genetics and biomarkers challenge beliefs that sex is binary. Discrimination against women and sex and gender minority (SGM) populations contributes to cognitive decline. Sociocultural factors lead to gender inequities in Alzheimer's disease and related dementias (ADRD) worldwide.
An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features
Salem, Ahmed Ebada , Zaki, Yehia H., El-Hussieny, Gamal, El-Noueam, Khaled I., Koppula, Bhasker R., Bustoros, Mark , Salama, Mohamed E. , Elsayes, Khaled M. , Morton, Kathryn A. , Salama, Mohamed , Shaaban, Akram M. , Covington, Matthew F.

Mayo Clinic

Cancers | November 23, 2021 | Volume: 13 | Issue: 22 | Pages: 5853

10.3390/cancers13225853 | PMID 34831006 Get It

Lymphoproliferative disorders (LPD) are conditions characterized by the uncontrolled proliferation of B or T-cell lines. They encompass a wide spectrum of abnormalities, which may be broadly classified as reactive processes or malignant diseases, such as lymphoma, based on their cellular clonality and clinical behavior. While some of these disorders are rare, they may be encountered sporadically in clinical practice, causing diagnostic dilemmas owing to overlap in their clinical and imaging features with more common disorders. The updated 4th edition WHO classification of lymphoid neoplasms was released in 2016 to incorporate the rapid clinical, pathological, molecular biology and cytogenetic advances of some of these disorders. Despite these updates, very little information is presented in the literature from the radiology perspective. The aim of this article is to familiarize radiologists and other physicians with certain rare variants of B-cell lymphoproliferative disorders with a focus on imaging features of these disorders, as well as to provide an overview of some important updates contained within the new WHO classification of lymphoid neoplasms.
Uncommon Variants of Mature T-Cell Lymphomas (MTCLs): Imaging and Histopathologic and Clinical Features with Updates from the Fourth Edition of the World Health Organization (WHO) Classification of Lymphoid Neoplasms
Salem, Ahmed Ebada , Zaki, Yehia H., El-Hussieny, Gamal, El-Noueam, Khaled I., Koppula, Bhasker R., Yang, Ming , Salama, Mohamed E. , Elsayes, Khaled M. , Salama, Mohamed , Shaaban, Akram M. , Covington, Matthew F.

Mayo Clinic

Cancers | October 18, 2021 | Volume: 13 | Issue: 20 | Pages: 5217

10.3390/cancers13205217 | PMID 34680362 Get It

Understanding the pathogenesis and molecular biology of malignant lymphomas is challenging, given the complex nature and incongruity of these disorders. The classification of lymphoma is continually evolving to account for advances in clinical, pathological, molecular biology and cytogenetic aspects, which impact our understanding of these disorders. The latest fourth edition of the WHO classification of lymphoid malignancies was released in 2016 to account for these changes. Additionally, unlike B-cell lymphomas (BCL), T-cell lymphomas (TCL) are uncommon, and may be sporadically experienced in clinical practice. These disorders are rare, thus early diagnosis is challenging for both physicians and radiologists, owing to the overlap in clinical and imaging features with other, more common disorders. We aim to discuss some rare variants of T-cell lymphomas, including clinicopathologic and imaging features, as well as to give a glimpse of the updates contained within the new 2016 WHO classification.
Ligament of Treitz: Anatomy, Relevance of Radiologic Findings, and Radiologic-Pathologic Correlation
Nassar, Sameh , Menias, Christine O. , Palmquist, Sarah , Pickhardt, Perry J. , Gaballah, Ayman H. , Elsayes, Khaled M. , Nada, Ayman , Shaaban, Akram M.

Mayo Clinic

American Journal of Roentgenology | February 10, 2021 | Volume: 216 | Issue: 4 | Pages: 927-934

10.2214/ajr.20.23273 | PMID 33566632 Get It

Cross-Sectional Imaging Evaluation of Vascular Lesions in the Gastrointestinal Tract and Mesentery
Zheng, Yanqiu, Shabana, Amr , Elsayes, Khaled M. , Hamid, Aws , Abdelaziz, Amr, Menias, Christine O. , Gaballah, Ayman H. , Shaaban, Akram M. , Liu, Peter Xiaoping

Mayo Clinic

Journal of Computer Assisted Tomography | November 13, 2020 | Volume: 44 | Issue: 6 | Pages: 870-881

10.1097/rct.0000000000001107 | PMID 33196596 Get It

Abstract Gastrointestinal (GI) tract and mesenteric vascular lesions can have various clinical presentations, of which GI bleeding is the most common. This collection of pathology is highly variable in etiology ranging from occlusive disease to vascular malformations to trauma to neoplasms which makes for a challenging workup and diagnosis. The advent of multiple imaging modalities and endoscopic techniques makes the diagnosis of these lesions more achievable, and familiarity with their various imaging findings can have a significant impact on patient management. In this article, we review the gamut of GI tract and mesenteric vascular lesions and their associated imaging findings.
The Lesser Sac and Foramen of Winslow: Anatomy, Embryology, and CT Appearance of Pathologic Processes
Elmohr, Mohab M. , Blair, Katherine J., Menias, Christine O. , Sandrasegaran, Kumar , Elsayes, Khaled M. , Nada, Ayman , Shaaban, Akram M.

Mayo Clinic

American Journal of Roentgenology | August 12, 2020 | Volume: 215 | Issue: 4 | Pages: 843-851

10.2214/ajr.19.22749 | PMID 32783559 Get It

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
Bedrose, Sara , Miller, Kevin C. , Altameemi, Lina, Nassar, Sameh , Daher, Marilyne , Eaton, Keith D. , Yorio, Jeffrey T. , Daniel, Davey B. , Bible, Keith C. , Ryder, Mabel , Miller, Kevin Charles, Habra, Mouhammed Amir , Ryder, Mabel , Miller, Kevin C , Ali, M. Shaaban , Garg, Naveen , Campbell, Matthew T. , Chintakuntlawar, Ashish V. , Habra, Mouhammed Amir

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 31, 2020 | Volume: 8 | Issue: 2 | Pages: e001009

10.1136/jitc-2020-001009 | PMID 32737143 Get It

Background There is no effective systemic therapy for metastatic adrenal cortical carcinoma (ACC) after failure of platinum-based chemotherapy. The efficacies of single-agent oral multikinase inhibitors (MKIs) or salvage immune checkpoint inhibitors (CPIs) have been very limited. It is unknown whether combining CPIs, such as pembrolizumab (PEM), with other therapies, such as MKIs, could yield higher response rates in ACC, yet this combination has shown promise in other cancers. Herein, we describe the first case series using PEM in combination with the MKI lenvatinib (LEN) in patients with progressive, metastatic ACC. Methods A retrospective case series describing the use of LEN/PEM as salvage therapy in patients with progressive/metastatic ACC. Results Eight patients were treated with the LEN/PEM combination therapy. Half were female, and the median age at time of diagnosis was 38 years (range 21–49). Three (37.5%) patients had hormonally active ACC. The median number of prior lines of systemic therapy was 4 (range 2–9). Six (75%) patients had had disease progression on prior CPIs and five (62.5%) patients had progressed on prior MKI therapy. The median progression-free survival was 5.5 months (95% CI 1.8–not reached) and median duration of therapy was 8.5 months (range 2–22). Two (25%) patients had a partial response, one (12.5%) patient had stable disease, and five (62.5%) patients had progressive disease. None of the eight patients stopped therapy because of adverse events. Conclusions In our small cohort of heavily pretreated patients with ACC, the combination of LEN/PEM was associated with objective responses in a subset of patients without significant toxicity. This combination should be formally investigated in phase II clinical trial with robust correlative studies to identify predictors for response.
Calcified Adrenal Lesions: Pattern Recognition Approach on Computed Tomography With Pathologic Correlation
Consul, Nikita , Venkatesan, Aradhana M. , Blair, Katherine J., Morshid, Ali , Menias, Christine O. , Elmohr, Mohab M. , Gaballah, Ayman H. , Elsayes, Khaled M. , Venkatesan, Aradhana M , Shaaban, Akram M.

Mayo Clinic

Journal of Computer Assisted Tomography | March 20, 2020 | Volume: 44 | Issue: 2 | Pages: 178-187

10.1097/rct.0000000000000980 | PMID 32195796 Get It

Abstract Incidental adrenal lesions are found in 2% to 10% of the population. The presence and pattern of calcifications, in conjunction with other clinical and imaging features, such as soft tissue attenuation, enhancement, and laterality, can aid in narrowing a differential diagnosis, thereby preventing unnecessary biopsies and avoiding delays in management. Calcified adrenal lesions can be categorized under the clinical and laboratory headings of normal adrenal function, hyperfunctioning adrenal tissue, and adrenal insufficiency. In this review, we provide an algorithmic approach to assessing calcified adrenal nodules with correlative radiologic findings.
Bleeding Liver Masses: Imaging Features With Pathologic Correlation and Impact on Management
Menias, Christine O. , Pickhardt, Perry J. , Gaballah, Ayman H. , Yedururi, Sireesha , Elsayes, Khaled M. , Thomas, Aaron J., Shaaban, Akram M.

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 8-16

10.2214/ajr.19.21240 | PMID 30973778 Get It